Moderna to Present at Upcoming Investor Conferences in November 2020

Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 11:25 a.m.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, November 2, 2020
Information
Tags: 
Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Life sciences, Branches of biology, Biology, Medical research, Vaccines, Moderna, Messenger RNA, Vaccine
Geotags: 
Massachusetts, United States
⚠ generated by AI ↴
Organisation: 
MODERNA
Summary
Key Points: 
  • Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 11:25 a.m.
  • A live webcast of each presentation will be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com .
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
  • Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.


Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:

  • Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020 at 8:00 a.m. ET.
  • Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 11:25 a.m. ET.

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) and the Coalition for Epidemic Preparedness Innovations (CEPI). Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Copyright: 
Copyright Business Wire 2020